SR9243 (1613028-81-1) is an LXR inverse agonist that significantly inhibits the Warburg effect and lipogenesis by reducing glycolytic and lipogenic gene expression. Induces apoptosis in a variety of cancer cell types including SW620 (IC₅₀ = 40 nM), HT-29 (IC₅₀ = 104 nM), DU-145 (IC₅₀ = 15 nM), PC-3 (IC₅₀ = 61 nM), NCI-H23 (IC₅₀ = 72 nM), HOP-62 (IC₅₀ = 26 nM) and MIAPACA-2 (IC₅₀= 18 nM). SR9243 is able to promote apoptotic cancer cell death without adversely affecting non-malignant cells.